Ocata Therapeutics
Marlborough
About Ocata Therapeutics
Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $72.8M
- Funding stage: M&A
- Last round: Post-IPO Debt (Aug 2015)
- Ticker: nasdaq:OCAT
- Website: ocata.com
- Phone: +1 (508) 756-1212
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ocata-therapeutics-2036077 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.